Supplementary Fig. 4. Extracellular signal-regulated kinase (Erk) and c-JUN N-terminal kinase (JNK) inhibitors inhibit the proliferation of vascular smooth muscle cells (VSMCs). A-10 cells pre-exposed to 50 μM Erk inhibitor (PD98059) or 50 μM JNK inhibitor (SP600125) for 1 hour are treated with 1 μM angiotensin II (Ang II), followed by treatment with or without exendin-4 (Ex-4; 100 nM), liraglutide (Lira; 100 nM), and dulaglutide (Dula; 100 nM) for 24 hours. VSMC proliferation is determined using MTT assay. CON, control. \(^*P<0.01\) when compared with the control cells, \(^{\dagger}P<0.01\) when compared with the Ang II-treated cells, \(^{\ddagger}P<0.01\) when compared with each inhibitor-untreated groups.